Dialybrid secured a €15M Series A round and announced first-in-human implant of its Silkothane Arteriovenous Graft for hemodialysis vascular access.
Dialybrid S
Dialybrid S.r.l. is a clinical-stage medical device company developing innovative vascular grafts for hemodialysis and other vascular applications. Its lead product, Silkothane® Arteriovenous Graft, is based on Silkothane®, a proprietary hybrid material combining silk fibroin and polyurethane.